In addition to the three NPVs, the FDA also announced the approval of an IND submission for DemeRx, which is investigating ...

Last month marked Women’s History Month, and in February there was International Day of Women and Girls in Science, too. But, ...

Oligonucleotide (oligo) therapies have been in development for decades. Recent advances in molecular design, chemistry, ...

Clinical trial sponsors and contract research organisations (CROs) are expanding clinical trials internationally to access ...

Regeneron has become the first company to get US approval for a gene therapy for congenital hearing loss, after the FDA gave ...

The regulator has sent a complete response letter (CRL) to AbbVie for trenibotulinumtoxinE (TrenibotE), a follow-up to its ...

Armed with new phase 3 data, Novo Nordisk has said it will file for approval of oral formulations of its GLP-1 agonist ...

Last year's $2.5 billion acquisition of Dynavax started to deliver, with a 2.1% rise in vaccine sales to €1.3 billion, driven ...

Berkeley, California biotech Ray Therapeutics, a specialist in the development of optogenetic therapies for eye disorders, ...

The first volunteers in a large-scale trial of Moderna's mRNA-based vaccine against bird flu – long considered to be a ...

The oral BTK inhibitor race in RMS is now a two-horse affair, with fenebrutinib vying against Novartis' remibrutinib, already ...

Just days after President Trump signed an executive order to broaden access to psychedelic medicines, the United States ...